Kivexa (abacavir;lamivudine)
- Region
- 🇪🇺 EU
- Active substance
- abacavir;lamivudine
- Company
- ViiV Healthcare BV
- Status
- Authorised
- Therapeutic area
- HIV Infections
- EU approval
- Thu 16 Dec 2004
- Application
- EMEA/H/C/000581
- ATC
- J05AR02
- Official record
- www.ema.europa.eu
Indication
Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg. Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trizivir Withdrawn · ViiV Healthcare BV
Follow Kivexa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.